April 2024
1. KARTSONAKI C, Yao P, Butt J, Jeske R, et al
   Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study.
   Int J Cancer. 2024;154:1423-1432.
   

   >> Share

   
   January 2024
2. ZHAO G, Shi X, Zhang L, Liang H, et al
   Comment on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
   Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34796.
   

   >> Share

   
   
3. KIM MN, Zhang X, Ahn SH
   Reply to: Comments on "Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients".
   Int J Cancer. 2024 Jan 11. doi: 10.1002/ijc.34797.
   

   >> Share

   
   August 2023
4. HA Y, Lim J, Chon YE, Kim MN, et al
   Five-year on-treatment variables-based PPACS model predicts subsequent hepatocellular carcinoma in entecavir/tenofovir-treated patients.
   Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34704.
   

   >> Share

   
   July 2023
5. KIM MN, Han K, Yoo J, Hwang SG, et al
   Diabetic MAFLD is associated with increased risk of hepatocellular carcinoma and mortality in chronic viral hepatitis patients.
   Int J Cancer. 2023 Jul 13. doi: 10.1002/ijc.34637.
   

   >> Share

   
   May 2023
6. ZENG D, Fang Y, Fei Y, Liang R, et al
   Treatment patterns and clinical outcomes of mantle cell lymphoma: A retrospective cohort study by CHOICE.
   Int J Cancer. 2023 May 19. doi: 10.1002/ijc.34565.
   

   >> Share

   
   March 2023
7. PETRICK JL, Florio AA, Zen J, Wang Y, et al
   Biomarkers of gut barrier dysfunction and risk of hepatocellular carcinoma in the REVEAL-HBV and REVEAL-HCV Cohort Studies.
   Int J Cancer. 2023 Mar 6. doi: 10.1002/ijc.34492.
   

   >> Share

   
   July 2022
8. FU P, Gong B, Li H, Luo Q, et al
   Combined identification of three lncRNAs in serum as effective diagnostic and prognostic biomarkers for hepatitis B virus-related hepatocellular carcinoma.
   Int J Cancer. 2022 Jul 8. doi: 10.1002/ijc.34201.
   

   >> Share

   
   May 2022
9. LIU T, Shi H
   Reply to: Comment on "Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: a prospective cohort study".
   Int J Cancer. 2022 May 10. doi: 10.1002/ijc.34113.
   

   >> Share

   
   
10. YANG Y, Chen XZ
    Comment on: "Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: a prospective cohort study".
    Int J Cancer. 2022 May 10. doi: 10.1002/ijc.34114.
    

    >> Share

    
    April 2022
11. CHEN S, Gao Y, Wang Y, Daemen T, et al
    The Combined Signatures of Hypoxia and Cellular Landscape Provides a Prognostic and Therapeutic Biomarker in HBV-Related Hepatocellular Carcinoma.
    Int J Cancer. 2022 Apr 25. doi: 10.1002/ijc.34045.
    

    >> Share

    
    December 2021
12. LIU T, Song C, Zhang Y, Siyin ST, et al
    Hepatitis B virus infection and the risk of gastrointestinal cancers among Chinese population: a prospective cohort study.
    Int J Cancer. 2021 Dec 2. doi: 10.1002/ijc.33891.
    

    >> Share

    
    June 2021
13. JI XW, Wang J, Shen QM, Li ZY, et al
    Dietary fat intake and liver cancer incidence: A population-based cohort study in Chinese men.
    Int J Cancer. 2021;148:2982-2996.
    

    >> Share

    
    
14. YU C, Song C, Lv J, Zhu M, et al
    Prediction and clinical utility of a liver cancer risk model in Chinese adults: A prospective cohort study of 0.5 million people.
    Int J Cancer. 2021;148:2924-2934.
    

    >> Share

    
    
15. JAQUET A, Boni SP, Boidy K, Tine J, et al
    Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.
    Int J Cancer. 2021 Jun 14. doi: 10.1002/ijc.33709.
    

    >> Share

    
    March 2021
16. SHI JF, Cao M, Wang Y, Bai FZ, et al
    Is it possible to halve the incidence of liver cancer in China by 2050?
    Int J Cancer. 2021;148:1051-1065.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share